Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. - Wikidata - awgldk - TriplyDB

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

http://www.wikidata.org/entity/Q37548944

about

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors Clinical significance of microcytosis in patients with primary myelofibrosis.Current and future treatment options for polycythemia vera.Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.Which clinical significance has automatic detection of very low levels of nucleated red blood cells in the peripheral blood?The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment

P2860

Q26750696-A7045A2D-11DE-4B37-855C-98482CF4533A Q28073296-6CF69C7B-64B6-49C5-B293-4A5B7F42B6B2 Q34276194-F5473728-A2F5-47CD-884F-48B471C9C080 Q35572748-5DEEEBFD-5761-4F61-B25C-C0243DAB28F7 Q36974354-EF7780E2-972B-4734-91B0-54EAAA916C46 Q38403573-67CC2450-D183-47AE-AE7F-60C143D881A1 Q38652831-2B3E9D0F-DE72-4E92-95EF-4A00B1304E75 Q42576698-7402C34F-2E72-4623-B14D-A8FF1DDA39F6 Q53111428-C4B60309-47EB-4424-B6B2-C113B1A55F60 Q58799997-FE2D5DA8-BF00-4766-A9A3-DF36C7E31C1E

P2860

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

http://www.wikidata.org/entity/Q37548944

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Myelofibrosis-associated compl ...... ions, and effects on outcomes.

@en

Myelofibrosis-associated compl ...... ions, and effects on outcomes.

@nl

type

label

Myelofibrosis-associated compl ...... ions, and effects on outcomes.

@en

Myelofibrosis-associated compl ...... ions, and effects on outcomes.

@nl

prefLabel

Myelofibrosis-associated compl ...... ions, and effects on outcomes.

@en

Myelofibrosis-associated compl ...... ions, and effects on outcomes.

@nl

P1433

Q37548944-44731973-7498-4F61-9B4A-FAF74BC451AF

P1476

Q37548944-A4900984-106A-4F0D-A7AB-CA1A0846285D

P2093

Q37548944-56082B82-AEA6-4BED-81E4-870D2407424B

Q37548944-58066BCE-8171-4E7A-9890-50890F70CED8

Q37548944-94CAA0C3-A995-4179-968D-B23FFE331C9A

P2860

Q37548944-0575B073-7F71-4695-B7FF-A2FEAF1DE180

Q37548944-087ACB0F-4FCB-44B6-89AC-EDA840E81FF4

Q37548944-13C03D9E-2DFF-4252-81E5-F2A97CE4684B

Q37548944-140DC3E4-966F-411B-AD78-74A61F8EEC02

Q37548944-183C82C6-C240-4CC4-9994-7D099AA4A935

Q37548944-1CBC1EBD-D6C7-44D8-BE5C-0E428BC2C156

Q37548944-1DC3071F-E9C5-458A-8D7D-E6D0A88001A0

Q37548944-26014C2A-73BB-4EDF-B5B8-AD9F81B8D0CD

Q37548944-2AB0AE5F-AA7C-452D-8F1F-52432184F4DE

Q37548944-2CB2DF1F-40E8-4718-824D-1A128A0F02B1

P304

Q37548944-D3D92AD0-71CC-4ACC-B989-86F72E3BBDF7

P31

Q37548944-0bbe4ef2-a72e-4e14-9e5b-f8d4a44e19b7

Q37548944-5709B4BC-1E78-4309-A858-AFDBCA590F5F

P356

Q37548944-D78407EE-F0CB-4464-A375-E5F3DD9EF407

P407

Q37548944-A0A556B6-FFC3-44B4-ADFC-D5B5464A3BCB

P478

Q37548944-68768652-6CBC-402D-B515-75AABD0BA599

P50

Q37548944-7585D735-E738-4E65-90C2-34186CB18AE2

P577

Q37548944-00F5C092-5F8D-4F81-851F-DDD522211977

P5875

Q37548944-7BAA572A-7587-445E-96C4-05F4F42E682C

P698

Q37548944-A5B5294A-A4F1-4262-9406-FC843E109210

P921

Q37548944-A8449EE6-5493-4B62-8AA7-AE38A7740503

P932

Q37548944-261A2EB9-7970-4C44-B8B8-7BD76B853052

P356

P1433

International Journal of General Medicine

P1476

Myelofibrosis-associated compl ...... ions, and effects on outcomes.

@en

P2093

Kris Vaddi

http://www.w3.org/2001/XMLSchema#string

Nicholas J Sarlis

http://www.w3.org/2001/XMLSchema#string

Tariq I Mughal

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

How I treat acquired aplastic anemia

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

European consensus on grading bone marrow fibrosis and assessment of cellularity.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

P304

89-101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJGM.S51800

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Srdan Verstovsek

P577

2014-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260118100

http://www.w3.org/2001/XMLSchema#string

P698

24501543

http://www.w3.org/2001/XMLSchema#string

P921

P932

3912063

http://www.w3.org/2001/XMLSchema#string